Skip to main content
. 2017 Jul 31;8(49):86816–86827. doi: 10.18632/oncotarget.19735

Figure 4. The cumulative sorting probability map of PFS and OS by meta regression analysis after correction.

Figure 4

Note: PFS = progression-free survival; OS = overall survival; A = erlotinib + placebo regimen; B = erlotinib + tivantinib regimen; C = erlotinib + celecoxib regimen; E = erlotinib + sunitinib regimen; G = erlotinib + sorafenib regimen.